Citations

Clear

815 citation(s) found for "Tang, Xi".

Abstract P06: Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma
Shivaram, Suganti, Tang, Hongwei , Yan, Huihuang , Tian, Shulan , Qin, Guyu , Anderson, Emilie, Bolarinwa, Abiola , Zepeda‐Mendoza, Cinthya , Dasari, Surendra , Kourelis, Taxiarchis , Kumar, Shaji , Bolarinwa, Abiola B , Tang, Hongwei, Sharma, Neeraj , Lehman, Stacey L. , Gomez, Felicia , Mitra, Amit , Baughn, Linda B.

Mayo Clinic

Blood Cancer Discovery | March 4, 2024 | Volume: 5 | Issue: 2_Supplement | Pages: P06-P06

10.1158/2643-3249.bcdsymp24-p06 Get It

Abstract Multiple myeloma (MM) is the most common blood cancer in African American (AA) individuals. AAs have an increased risk of developing Monoclonal Gammopathy of Undetermined Significance (MGUS) and MM compared to non-Hispanic White (NHW) individuals. While several studies have shown a pivotal role for the immune tumor microenvironment (iTME) in MM pathogenesis, the composition of the iTME in AAs with MM is under investigated. Viably frozen whole bone marrow (BM) aspirates from 128 individuals (53 AA and 75 NHW) with either MM (n=65), MGUS (n=28), smoldering MM (SMM, n=13), or healthy controls (n=22) were evaluated by single cell RNA-sequencing (scRNA-seq) or mass cytometry (CyTOF). We characterized 34 (14 AA and 20 NHW) by scRNA-seq and 94 (39 AA and 55 NHW) by CyTOF. CyTOF samples were stained with Maxpar Direct Immune Profiling Assay Kit (Fluidigm), acquired on a Helios mass cytometer and analyzed in Cytobank. Data were analyzed by logistic equivalent regression model with p<0.05 for significance. ScRNA-seq samples were processed as in Yao, 2022. Data were normalized using scvi-tools and clustered by Uniform manifold approximation and projection (UMAP). Differentially expressed markers between clusters were identified using Model-based Analysis of Single-cell Transcriptomics (MAST) in Seurat R package at FDR < 0.05 and log2 fold change > 0.55. ScRNA-seq of the CD45+ non-tumor lymphocytes revealed 17 immune populations (HSC, erythroblast, MDSC, GMP, CD1c+ DC, CD4+ and CD8+ T cell, CD14+ M1 macrophage, CD16+monocyte, monocyte, pDC, naïve B, pre-B, pro-B, memory B, NK/MAIT). CD3E/D+cells were clustered into naïve/central memory (CCR7+, LEF1+, SELL+), memory (GZMK+), effector (GZMB+, GZMH+, FGFBP2+), g/d (TRDC+), MAIT (SLC4A10+, KLRB1+) and IFN CD8+ T cells (IFIT1+, IFIT2+,IFIT3+). Disease progression was associated with increases in median CD4+ and CD8+ GZMK+ T cells, memory B cells and a reduction in all monocyte clusters. Within the diseased cohort in comparison to NHW patients, AA patients had increased CD3+ T cells (CD4 and CD8+) (AA 57.5% vs. NHW 44.3%) and a reduction in overall monocytes (AA 10.5% vs. 26.5%). These results were validated by CyTOF, which confirmed an increase in CD3+ T cells (AA 53.7% vs. NHW 35.7%, p<0.001) including increases in CD8+ (AA 7.0% vs. NHW 3.2%, p<0.05) and CD4+ terminal effector T cells (AA 5.7% vs. NHW 2.7%, p<0.05) and a reduction in monocytes (AA 18.3% vs. NHW 26.6%) among AAs. After adjusting for age and sex, AAs retained an increase in T cells (OR 1.59 (95%CI 1.2-2.01, p=0.00023)) and a reduction in monocytes (OR 0.88 (95%CI 0.78-1, p=0.045)). Despite the increase in CD8+ T cells in AA patients, we identified reduced GZMK+ T cells and reductions in exhaustion markers (TIGIT, LAG3, TOX) in CD8+ T cells in comparison to NHWs. Nevertheless, the distribution of the immune populations was similar between healthy AA and NHW individuals. Our multiomics approach to characterize the iTME identified significant differences among AA compared to NHW patients with MM. Citation Format: Suganti Shivaram, Hongwei Tang, Huihuang Yan, Shulan Tian, Guyu Qin, Emilie Anderson, Neeraj Sharma, Abiola Bolarinwa, Cinthya Zepeda-Mendoza, Stacey Lehman, Felicia Gomez, Amit Mitra, Surendra Dasari, Taxiarchis Kourelis, Shaji Kumar, Linda Baughn. Characterization of the Immune Tumor Microenvironment in a Diverse Cohort of Patients with Multiple Myeloma [abstract]. In: Proceedings of the Blood Cancer Discovery Symposium; 2024 Mar 4-6; Boston, MA. Philadelphia (PA): AACR; Blood Cancer Discov 2024;5(2_Suppl):Abstract nr P06.
Abstract B002: Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer
Rodman, Esther , Emch, Michael , Bajaj, Archit, Hou, Xiaonan , Weroha, S. John , Hawse, John R. , Tang, Xiaojia , Kaufmann, Scott H. , Kalari, Krishna R.

Mayo Clinic

Cancer Research | March 4, 2024 | Volume: 84 | Issue: 5_Supplement_2 | Pages: B002-B002

10.1158/1538-7445.ovarian23-b002 Get It

Abstract Ovarian cancer is the most fatal of all female reproductive cancers due to its late detection, aggressive nature, and propensity to develop resistance to current standards of care. Despite initial responses to first line platinum- and paclitaxel-based chemotherapies, >70% of ovarian cancers recur with increasingly resistant disease. Targeted therapies, including PARP-inhibitors (PARPi) and VEGF-inhibitors, are being included in the front-line setting; and while they have improved progression-free survival in a subset of patients, they have thus far failed to improve overall survival in patients without specific genetic signatures. With the broad uptake of PARPi, PARPi-resistance is becoming common. Once resistance develops, nearly all patients die of their disease and there is an obvious need to elucidate the basis for chemotherapy- and PARPi-resistance and devise novel approaches to overcome resistance. Using a small molecule drug screen, we identified lestaurtinib, a known tyrosine kinase inhibitor as a potent inhibitor of treatment naive and highly advanced models of ovarian cancer. Lestaurtinib was originally developed to target FLT3, a protein not expressed in any ovarian cancer models we’ve tested. To identify lestaurtinib targets, we preformed phospho-proteomics in parallel with RNAseq and discovered the JAK/STAT signally pathway as a top hit. We confirmed that essential components of JAK/STAT signaling are constitutively activated in chemotherapy- and PARPi-resistant cells, suggesting that induction of this pathway may drive resistance. Importantly, we found that lestaurtinib-sensitive patient-derived-xenografts (PDXs) exhibited higher expression of multiple JAK/STAT signaling pathway members compared to PDXs that did not respond to lestaurtinib. Genetic knockdown of STAT1 and STAT3 via siRNA, or knockout via CRISPR/Cas9, resulted in significant growth inhibition of sensitive and resistant models, confirming their importance in maintaining cell viability and progression. Combining lestuartinib with standard-of-care cisplatin or olaparib, a PARPi, was shown to be synergistic in multiple models, indicating that pharmacological inhibition of JAK/STAT signaling has the potential to alleviate drug resistance. Finally, we assessed a panel of JAK/STAT inhibitors that interfere at various levels of the pathway and found profound differences in their ability to block STAT-phosphorylation and inhibit cell proliferation. Thus, it is critical to further define the mechanisms by which these drugs function to selectively suppress JAK/STAT signaling in order to elucidate specific nodes of the pathway that drive ovarian cancer progression. Ongoing studies are aimed at identifying the unique roles of STAT1 and STAT3, the specific contributions of their tyrosine and serine phosphorylation, and the relevance of up-/down-stream mediators of the JAK/STAT pathway on ovarian cancer cell growth with the goal of informing future clinical trials. Citation Format: Esther Rodman, Michael Emch, Archit Bajaj, Xiaojia Tang, Xiaonan Hou, Scott Kaufmann, Krishna Kalari, John Weroha, John Hawse. Exploiting JAK/STAT signaling to inhibit highly advanced and resistant forms of ovarian cancer [abstract]. In: Proceedings of the AACR Special Conference on Ovarian Cancer; 2023 Oct 5-7; Boston, Massachusetts. Philadelphia (PA): AACR; Cancer Res 2024;84(5 Suppl_2):Abstract nr B002.
CALGB 80802 (Alliance): Impact of Sorafenib with and without Doxorubicin on Hepatitis C Infection in Patients with Advanced Hepatocellular Carcinoma
Abou‐Alfa, Ghassan K. , Geyer, Susan M. , Nixon, Andrew B. , Innocenti, Federico , Shi, Qian , Kumthekar, Priya , Jacobson, Sawyer , Dika, Imane El , Yaqubie, Amin , Lopez, Juan , Huang, Binhui , Wen, Yujia , Knox, Jennifer J. , Rajdev, Lakshmi , Meyerhardt, Jeffrey A. , El Dika, Imane , Tang, Yi-Wei , Wen, Yujia , Schwartz, Lawrence H , El-Khouiery, Anthony B , Knox, Jennifer J , Rajdev, Lakshmi , Bertagnolli, Monica M , Meyerhardt, Jeffrey A , O'Reilly, Eileen M , Venook, Alan P , Shi, Qian , Abou-Alfa, Ghassan K , Nixon, Andrew B , Tang, Yi‐Wei , Schwartz, Lawrence H. , El-Khoueiry, Anthony B. , Bertagnolli, Monica M. , O’Reilly, Eileen M. , Venook, Alan P.

Mayo Clinic

Cancer Research Communications | February 16, 2024 | Volume: 4 | Issue: 3 | Pages: 682-690

10.1158/2767-9764.crc-22-0516 | PMID 38363156 Get It

Abstract Sorafenib blocks nonstructural protein 5A (NS5A)-recruited c-Raf–mediated hepatitis C virus (HCV) replication and gene expression. Release of Raf-1-Ask-1 dimer and inhibition of Raf-1 via sorafenib putatively differ in the presence or absence of doxorubicin. Cancer and Leukemia Group B (CALGB) 80802 (Alliance) randomized phase III trial of doxorubicin plus sorafenib versus sorafenib in patients with advanced hepatocellular carcinoma (HCC), showed no improvement in median overall survival (OS). Whether HCV viral load impacts therapy and whether any correlation between HCV titers and outcome based on HCV was studied. In patients with HCV, HCV titer levels were evaluated at baseline and at multiple postbaseline timepoints until disease progression or treatment discontinuation. HCV titer levels were evaluated in relation to OS and progression-free survival (PFS). Among 53 patients with baseline HCV data, 12 patients had undetectable HCV (HCV-UN). Postbaseline HCV titer levels did not significantly differ between treatment arms. One patient in each arm went from detectable to HCV-UN with greater than 2 log-fold titer levels reduction. Aside from these 2 HCV-UN patients, HCV titers remained stable on treatment. Patients who had HCV-UN at baseline were 3.5 times more likely to progress and/or die from HCC compared with HCV detectable (HR = 3.51; 95% confidence interval: 1.58–7.78; P = 0.002). HCV titer levels remained unchanged, negating any sorafenib impact onto HCV titer levels. Although an overall negative phase III study, patients treated with doxorubicin plus sorafenib and sorafenib only, on CALGB 80802 had worse PFS if HCV-UN. Higher levels of HCV titers at baseline were associated with significantly improved PFS. Significance: Sorafenib therapy for HCC may impact HCV replication and viral gene expression. In HCV-positive patients accrued to CLAGB 80802 phase III study evaluating the addition of doxorubicin to sorafenib, HCV titer levels were evaluated at baseline and different timepoints. Sorafenib did not impact HCV titer levels. Despite an improved PFS in patients with detectable higher level HCV titers at baseline, no difference in OS was noted.
Response to: Comment on: COG Diagnostic Imaging Committee/SPR Oncology Committee White Papers
Towbin, Alexander J. , Tang, Elizabeth , Thacker, Paul G. , McCarville, M. Beth , Thacker, Paul G , Alazraki, Adina

Mayo Clinic

Pediatric Blood & Cancer | January 31, 2024 | Volume: 71 | Issue: 4 | Pages: No page available

10.1002/pbc.30900 | PMID 38296784 Get It

Lung Cancer Screening Results Among Population of Different Genders, Ages, Smokers and Non-smokers: A Study Based on Real World Data
Bao, Ting , Li, Zhenzhen , Ji, Guiyi , Tang, Huairong , Yang, Hanwei , Huang, Yan , Wang, Youjuan , Yang, Ping , Li, Weimin

Mayo Clinic

No container title available | January 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.22541/au.170666202.25160823/v1 Get It

Background Analysis of the real-world data of low-dose spiral CT screening of healthy physical examination population in Southwest China from 2006 to 2017, discussed the standard of low-dose spiral CT screening for high-risk population of lung cancer in China. Methods Incorporate all team subjects who have undergone LDCT screenings at the Health Management Center of West China Hospital of Sichuan University between 2006 and 2017, and analyze the cumulative incidence and age-standardized (Segi population) incidence of lung cancer in the whole population; finally, analysis the age-specific, smoking and non-smokers’ lung cancer incidence. Results A total of 15,996 people who met the enrollment conditions and participated in the LDCT lung cancer screening were included. The average screening interval was 1.12±0.26 years, and the average follow-up time was 5.43±0.82 years; The cumulative number of lung cancer cases with negative baseline screening was 56 cases, and the cumulative incidence rate of lung cancer was 122.1/100,000 (the world standard rate is 60.6/100,000), of which males were 100.0/100,000 (the world standard rate is 45.3/100,000) and women were 156.6 /100,000 (the world standard rate is 94.7/100,000); the cumulative incidence of lung cancer in the smoking group is higher than that in the non-smoking group for both males and females, but the cumulative incidence of lung cancer in the non-smokers of the female population (146.3/100,000) is higher than that of the male population (86.5/10 Million). Conclusion In the real world study of lung cancer screening in Chinese population, we should consider setting different standards for high-risk groups of lung cancer by gender or smoking and non-smokers.
Sex differences in trends and outcomes of acute myocardial infarction with mechanical complications in the United States
Rivera, Frederick Berro , Salva, Faye, Gonzales, Jacques Simon T., Whoy, Sung , Lumbang, Grace Nooriza O. , Planek, Isabel, Cruz, Mark Dela, Suboc, Tisha, Collado, F. , Cha, Sung Whoy , Lara-Breitinger, Kyla , Tang, Samantha , Kaur, Gurleen , Lara-Breitinger, Kyla M , Enriquez, Jonathan R. , Shah, Nishant , Santos Volgman, Annabelle

Mayo Clinic

Expert Review of Cardiovascular Therapy | January 29, 2024 | Volume: 22 | Issue: 1-3 | Pages: 111-120

10.1080/14779072.2024.2311707 | PMID 38284754 Get It

Whole‐exome sequencing of Nigerian benign prostatic hyperplasia reveals increased alterations in apoptotic pathways
White, Jason , Adeniji, Kayode , Jibrin, Paul, Obafunwa, John , Ogo, Chidiebere, Popoola, Ademola , Fatiregun, Omolara , Oluwole, Olabode P., Thorpe, Roland J. , Karanam, Balasubramanyam , Polak, Paz , Brignole, Kathryn R. , Dean‐Colomb, Windy, Odedina, Folake T., Yates, Clayton , White, Jason A , Popoola, Ademola A , Brignole, Kathryn R , Yates, Clayton , Fatiregun, Omolara , Kaninjing, Ernest , Faruk, Mohammed , Elhussin, Isra , Ambs, Stefan , Tang, Wei , Davis, Melissa , Campbell, Moray J. , Rotimi, Solomon O.

Mayo Clinic

The Prostate | January 9, 2024 | Volume: 84 | Issue: 5 | Pages: 460-472

10.1002/pros.24662 | PMID 38192023 Get It

AbstractBackgroundThrough whole‐exome sequencing of 60 formalin‐fixed paraffin‐embedded Nigerian (NGRn) benign prostatic hyperplasia (BPH) samples, we identified germline and somatic alterations in apoptotic pathways impacting BPH development and progression. Prostate enlargement is a common occurrence in male aging; however, this enlargement can lead to lower urinary tract symptoms that negatively impact quality of life. This impact is disproportionately present in men of African ancestry. BPH pathophysiology is poorly understood and studies examining non‐European populations are lacking.MethodsIn this study, NGRn BPH, normal prostate, and prostate cancer (PCa) tumor samples were sequenced and compared to characterize genetic alterations in NGRn BPH.ResultsTwo hundred and two nonbenign, ClinVar‐annotated germline variants were present in NGRn BPH samples. Six genes [BRCA1 (92%), HSD3B1 (85%), TP53 (37%), PMS2 (23%), BARD1 (20%), and BRCA2 (17%)] were altered in at least 10% of samples; however, compared to NGRn normal and tumor, the frequency of alterations in BPH samples showed no significant differences at the gene or variant level. BRCA2_rs11571831 and TP53_rs1042522 germline alterations had a statistically significant co‐occurrence interaction in BPH samples. In at least two BPH samples, 173 genes harbored somatic variants known to be clinically actionable. Three genes (COL18A1, KIF16B, and LRP1) showed a statistically significant (p < 0.05) higher frequency in BPH. NGRn BPH also had five gene pairs (PKD1/KIAA0100, PKHD1/PKD1, DNAH9/LRP1B, NWD1/DCHS2, and TCERG1/LMTK2) with statistically significant co‐occurring interactions. Two hundred and seventy‐nine genes contained novel somatic variants in NGRn BPH. Three genes (CABP1, FKBP1C, and RP11‐595B24.2) had a statistically significant (p < 0.05) higher alteration frequency in NGRn BPH and three were significantly higher in NGRn tumor (CACNA1A, DMKN, and CACNA2D2). Pairwise Fisher's exact tests showed 14 gene pairs with statistically significant (p < 0.05) interactions and four interactions approaching significance (p < 0.10). Mutational patterns in NGRn BPH were similar to COSMIC (Catalog of Somatic Mutations in Cancer) signatures associated with aging and dysfunctional DNA damage repair.ConclusionsNGRn BPH contained significant germline alteration interactions (BRCA2_rs11571831 and TP53_rs1042522) and increased somatic alteration frequencies (LMTK2, LRP1, COL18A1, CABP1, and FKBP1C) that impact apoptosis. Normal prostate development is maintained by balancing apoptotic and proliferative activity. Dysfunction in either mechanism can lead to abnormal prostate growth. This work is the first to examine genomic sequencing in NGRn BPH and provides data that fill known gaps in the understanding BPH and how it impacts men of African ancestry.
TREM2‐IGF1 Mediated Glucometabolic Enhancement Underlies Microglial Neuroprotective Properties During Ischemic Stroke
Yang, Sheng , Qin, Chuan, Chu, Yun‐Hui, Tang, Yue , Zhou, Luo‐Qi , Zhang, Hang , Dong, Ming‐Hao , Pang, Xiao‐Wei, Chen, Lian , Wu, Long‐Jun , Wang, Wei , Wang, Wei , Wu, Long-Jun , Qin, Chuan, Chen, Man , Tian, Dai‐Shi

Mayo Clinic

Advanced Science | December 27, 2023 | Volume: 11 | Issue: 10 | Pages: No page available

10.1002/advs.202305614 | PMID 38151703 Get It

Abstract Microglia, the major resident immune cells in the central nervous system, serve as the frontline soldiers against cerebral ischemic injuries, possibly along with metabolic alterations. However, signaling pathways involved in the regulation of microglial immunometabolism in ischemic stroke remain to be further elucidated. In this study, using single‐nuclei RNA sequencing, a microglial subcluster up‐regulated in ischemic brain tissues is identified, with high expression of Igf1 and Trem2, neuroprotective transcriptional signature and enhanced oxidative phosphorylation. Microglial depletion by PLX3397 exacerbates ischemic brain damage, which is reversed by repopulating the microglia with high Igf1 and Trem2 phenotype. Mechanistically, Igf1 serves as one of the major down‐stream molecules of Trem2, and Trem2‐Igf1 signaling axis regulates microglial functional and metabolic profiles, exerting neuroprotective effects on ischemic stroke. Overexpression of Igf1 and supplementation of cyclocreatine restore microglial glucometabolic levels and cellular functions even in the absence of Trem2. These findings suggest that Trem2‐Igf1 signaling axis reprograms microglial immunometabolic profiles and shifts microglia toward a neuroprotective phenotype, which has promising therapeutic potential in treating ischemic stroke.
The Pituitary Adenylate Cyclase Activating Polypeptide Levels are Associated with Pathological Features of Alzheimer’s Disease (P4.201)
Shi, Jiong , Han, Peiwei , Tang, Zhiwei , Yin, Junxiang , Beach, Thomas G. , Caselli, Richard J. , Reiman, EM, Han, P, Baxter, Leslie C. , Liang, Winnie S. , Reiman, Eric M.

Mayo Clinic

Neurology | December 7, 2023 | Volume: 82 | Issue: 10_supplement | Pages: No page available

10.1212/wnl.82.10_supplement.p4.201 Get It

Severe adolescent-onset limb-girdle muscular dystrophy due to a novel homozygous nonsense BVES mutation (1497)
Tang, Connie, Beecher, Grayson , Liewluck, Teerin

Mayo Clinic

Neurology | December 7, 2023 | Volume: 96 | Issue: 15_supplement | Pages: No page available

10.1212/wnl.96.15_supplement.1497 Get It